Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: several efficacy/mechanism and key counseling items (BPH indication, smooth muscle relaxation, IFIS counseling) match the provided label excerpts, but multiple overbroad/unsupported mechanistic, timing, incidence, comparative, and perioperative discontinuation claims are not supported by the supplied text.
Category Scores
Accurate Statements
Silodosin is used to treat the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
1 INDICATIONS AND USAGE: "indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)"
Silodosin relaxes muscles in the prostate and bladder neck.
12.1 Mechanism of Action: blockade can cause smooth muscle in these tissues to relax (includes prostate and bladder base/bladder neck)
Relaxation by silodosin can improve urine flow.
12.1 Mechanism of Action: "resulting in an improvement in urine flow"
Silodosin is classified as an alpha-1 adrenergic receptor antagonist.
1 INDICATIONS AND USAGE and 11 DESCRIPTION: "selective alpha-1 adrenergic receptor antagonist" / "selective antagonist of alpha-1 adrenoreceptors"
Silodosin selectively blocks alpha-1A adrenergic receptors.
12.1 Mechanism of Action: binds with high affinity to the alpha-1A subtype
By blocking alpha-1A adrenergic receptors, silodosin causes smooth muscle in the prostate and bladder neck to relax.
12.1 Mechanism of Action: relaxation of prostate/bladder base/bladder neck via alpha-1 adrenoreceptor blockade; high affinity for alpha-1A
Common side effects of silodosin include dizziness.
17 PATIENT COUNSELING INFORMATION: postural hypotension symptoms (such as dizziness)
Common side effects of silodosin include a decrease in ejaculate volume.
17 PATIENT COUNSELING INFORMATION: "orgasm with reduced or no semen"
Men taking silodosin who are planning cataract or other eye surgery should inform their ophthalmologist.
6 ADVERSE REACTIONS 5.7: "Patients planning cataract surgery should be told to inform their ophthalmologist that they are taking RAPAFLO"; 17: "before cataract surgery or other procedures"
Silodosin can cause Intraoperative Floppy Iris Syndrome (IFIS).
6 ADVERSE REACTIONS 5.7: "Intraoperative Floppy Iris Syndrome has been observed" in some patients on alpha-1 blockers or previously treated
The original brand-name version of silodosin is marketed by Kissei Pharmaceutical Co., Ltd.
17 PATIENT COUNSELING INFORMATION: "Under license from: Kissei Pharmaceutical Co., Ltd."
Unsupported Statements
Alpha-1A adrenergic receptors are abundant in the prostate.
No "abundant" characterization in provided label excerpts.
Relaxation decreases the pressure on the urethra.
Provided label excerpts do not state urethral pressure decrease.
Decreased urethral pressure facilitates easier passage of urine.
Provided label excerpts do not describe urethral pressure or that specific causal pathway.
Patients typically begin to experience relief from BPH symptoms within a few weeks of starting silodosin.
Provided label excerpts show symptom decrease starting at early observations and sustained through 12 weeks, but do not support the specific phrasing/timing "within a few weeks".
The full benefits of silodosin may become apparent over a longer period of consistent use.
Provided label excerpts support sustained improvement through 12 weeks, but do not specifically state "full benefits" or a time-to-max benefit concept.
Common side effects of silodosin include lightheadedness.
Label excerpts mention dizziness/postural hypotension symptoms but do not explicitly state "lightheadedness".
Common side effects of silodosin include abnormal ejaculation such as retrograde ejaculation.
Provided label excerpts state reduced/no semen as the most common side effect, but do not explicitly mention retrograde ejaculation.
Silodosin is used for the long-term management of BPH in many patients.
Provided excerpts describe efficacy over 12 weeks; they do not state long-term management in many patients.
Silodosin is more selective for the alpha-1A receptor subtype than less selective alpha-blockers.
Provided excerpts show alpha-1A high affinity/selectivity but do not compare against other alpha-blockers.
Silodosin selectivity may lead to a different side effect profile compared with less selective alpha-blockers.
No comparative side effect profile discussion versus other alpha-blockers in provided excerpts.
All alpha-blockers can cause dizziness.
No label statement in provided excerpts about all alpha-blockers causing dizziness.
Silodosin has a higher incidence of ejaculatory dysfunction due to its specific action.
Provided excerpts do not include incidence comparisons or a mechanism-based "higher incidence" claim.
IFIS can increase the risk of complications during eye surgery.
Provided label excerpt describes IFIS characteristics but does not state increased complication risk.
It is often recommended to discontinue silodosin before cataract or other eye surgery.
Provided label excerpts instruct informing ophthalmologist, but do not recommend discontinuation prior to surgery.
After patents expire, other pharmaceutical companies may produce and market generic versions of silodosin.
No patent/generic market statements in provided label excerpts.
Contradictions
Important Omissions
Dose and administration instructions (e.g., dosing strength/frequency with meal) were not evaluated due to absence in the provided extracted claims, and dosing safety/adjustment details were not provided in the label excerpts supplied.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by the provided label excerpts (e.g., perioperative discontinuation recommendation, complication-risk escalation from IFIS, specific timing, and retrograde ejaculation). While none directly contradict the provided excerpts, unsupported specificity could mislead counseling or expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple mechanistic/timing/incidence/comparative and perioperative discontinuation claims are not supported by the supplied label excerpts.
Suggested Improvement
Remove or rephrase unsupported specifics not present in the provided label text (e.g., "abundant", urethral-pressure decrease, "within a few weeks", retrograde ejaculation, generic/patent marketing, IFIS leading to increased complications, and discontinuation-before-surgery recommendation). Stick to label-supported statements: indication, alpha-1A high affinity and relaxation improving urine flow/BPH symptoms, dizziness/postural hypotension counseling, and informing ophthalmologist about RAPAFLO/IFIS.